Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
28497898
DOI
10.1002/cncr.30767
Knihovny.cz E-resources
- Keywords
- Philadelphia-positive, child, chronic myeloid leukemia, cytogenetic, imatinib,
- MeSH
- Survival Analysis MeSH
- Chromosome Aberrations statistics & numerical data MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis drug therapy genetics mortality MeSH
- Genetic Predisposition to Disease epidemiology MeSH
- Internationality MeSH
- Kaplan-Meier Estimate MeSH
- Real-Time Polymerase Chain Reaction methods MeSH
- Humans MeSH
- Chromosomes, Human, Pair 22 genetics MeSH
- Chromosomes, Human, Pair 9 genetics MeSH
- Follow-Up Studies MeSH
- Statistics, Nonparametric MeSH
- Disease-Free Survival MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Drug Administration Schedule MeSH
- Treatment Outcome MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: In the adult population with newly diagnosed chronic myeloid leukemia (CML), variant translocations are usually not considered to be impairing the prognosis, whereas some additional cytogenetic abnormalities (ACAs) are associated with a negative impact on survival. Because of the rarity of CML in the pediatric population, such abnormalities have not been investigated in a large group of children with CML. METHODS: The prognostic relevance of variant t(9;22) and ACAs at diagnosis was assessed in 301 children with CML in the chronic phase who were enrolled in the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. RESULTS: Overall, 19 children (6.3%) presented with additional cytogenetic findings at diagnosis: 5 children (1.7%) had a variant t(9;22) translocation, 13 children (4.3%) had ACAs, and 1 had both. At 3 years, for children with a classic translocation, children with ACAs, and children with a variant t(9;22) translocation who were treated with imatinib as frontline therapy, the probability of progression-free survival (PFS) was 95% (95% confidence interval [CI], 91%-97%), 100%, and 75% (95% CI, 13%-96%), respectively, and the probability of overall survival (OS) was 98% (95% CI, 95%-100%), 100% (95% CI, 43%-98%), and 75% (95% CI, 13%-96%), respectively. No statistical difference was observed between the patients with classic cytogenetic findings and those with additional chromosomal abnormalities in terms of PFS and OS. CONCLUSIONS: In contrast to adults with CML, additional chromosomal abnormalities observed at diagnosis do not seem to have a significant prognostic impact. Cancer 2017;123:3609-16. © 2017 American Cancer Society.
Children's Cancer Research Institute and St Anna Children's Hospital Vienna Austria
Department of Pediatric Hematology Robert Debré Hospital Paris France
Department of Pediatric Hematology Uludağ University Hospital Görükle Bursa Turkey
Department of Pediatric Oncology University Children's Hospital Bratislava Slovakia
Department of Pediatrics Carl Gustav Carus University Hospital Dresden Germany
Department of Pediatrics Ghent University Hospital Ghent Belgium
Department of Pediatrics Prince of Wales Hospital Chinese University of Hong Kong Hong Kong China
Department of Pediatrics Rigshospitalet University Hospital Copenhagen Denmark
Department of Pediatrics Saint George Hospital University Medical Centre Beirut Lebanon
Dutch Childhood Oncology Group the Hague the Netherlands
INSERM Clinical Investigation Center 1402 Poitiers University Poitiers France
References provided by Crossref.org
